Comparison of serum thyrotrophin concentrations determined by a third generation assay in patients with various types of overt and subclinical thyrotoxicosis

Recent increases in the sensitivity of methods used to measure TSH, especially third generation assays, have enabled separation of partial from complete pituitary suppression in patients with thyrotoxicosis. We have investigated the use of a sensitive chemiluminescent enzymeimmunoassay in the differential diagnosis of thyrotoxicosis.

[1]  P. Yeo,et al.  Subclinical thyrotoxicosis. , 1998, Advances in internal medicine.

[2]  J. Konishi,et al.  Subclinical Graves’ disease as a cause of subnormal TSH levels in euthyroid subjects , 1997, Journal of endocrinological investigation.

[3]  K. Kuma,et al.  Incomplete thyrotroph suppression determined by third generation thyrotropin assay in subacute thyroiditis compared to silent thyroiditis or hyperthyroid Graves' disease. , 1997, The Journal of clinical endocrinology and metabolism.

[4]  G. Beckett,et al.  Interlaboratory/intermethod differences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on reliability of measurement of subnormal concentrations of TSH. , 1995, Clinical chemistry.

[5]  J. Franklyn,et al.  Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. , 1994, The Journal of clinical endocrinology and metabolism.

[6]  P. Rae,et al.  Chemiluminescent third-generation assay (Amerlite TSH-30) of thyroid-stimulating hormone in serum or plasma assessed. , 1993, Clinical chemistry.

[7]  H. Hatabu,et al.  Sonography of subacute thyroiditis: Changes in the findings during the course of the disease , 1990, Journal of clinical ultrasound : JCU.

[8]  D. Ross,et al.  Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminescent assay. , 1989, The Journal of clinical endocrinology and metabolism.

[9]  H. Hatabu,et al.  Role of thyrotropin receptor antibodies in the development of hyperthyroidism: follow-up studies on nine patients with Graves' disease. , 1989, The Journal of clinical endocrinology and metabolism.

[10]  D. Ehrmann,et al.  Limitations to the use of a sensitive assay for serum thyrotropin in the assessment of thyroid status. , 1989, Archives of internal medicine.

[11]  H. Hatabu,et al.  STUDIES ON THYROTROPHIN RECEPTOR ANTIBODIES IN PATIENTS WITH EUTHYROID GRAVES' DISEASE , 1988, Clinical endocrinology.

[12]  H. Studer,et al.  3 Toxic nodular goitre , 1985 .

[13]  J. Hamburger.  Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. , 1980, The Journal of clinical endocrinology and metabolism.

[14]  S C Werner,et al.  Classification of the eye changes of Graves' disease. , 1969, American journal of ophthalmology.